Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
studies
multiple myeloma - 2nd line (L2), pembrolizumab based treatment vs. pomalidomide and dexamethasone, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results KEYNOTE-183, 2019 1.61 [0.91; 2.85]
1.61 [0.91 ; 2.85 ] KEYNOTE-183, 2019 1 0% 249 NA not evaluable progression or deaths (PFS)detailed results KEYNOTE-183, 2019 1.53 [1.05; 2.22]
1.53 [1.05 ; 2.22 ] KEYNOTE-183, 2019 1 0% 249 NA not evaluable DCRdetailed results KEYNOTE-183, 2019 1.01 [0.51; 2.01]
1.01 [0.51 ; 2.01 ] KEYNOTE-183, 2019 1 0% 249 NA not evaluable objective responses (ORR)detailed results KEYNOTE-183, 2019 0.78 [0.46; 1.30]
0.78 [0.46 ; 1.30 ] KEYNOTE-183, 2019 1 0% 249 NA not evaluable AE (any grade)detailed results KEYNOTE-183, 2019 5.13 [0.59; 44.58]
5.13 [0.59 ; 44.58 ] KEYNOTE-183, 2019 1 0% 241 NA not evaluable AE (grade 3-4)detailed results KEYNOTE-183, 2019 1.71 [0.98; 2.99]
1.71 [0.98 ; 2.99 ] KEYNOTE-183, 2019 1 0% 241 NA not evaluable AE leading to death (grade 5)detailed results KEYNOTE-183, 2019 4.78 [1.33; 17.23]
4.78 [1.33 ; 17.23 ] KEYNOTE-183, 2019 1 0% 241 NA not evaluable SAE (any grade)detailed results KEYNOTE-183, 2019 1.93 [1.16; 3.23]
1.93 [1.16 ; 3.23 ] KEYNOTE-183, 2019 1 0% 241 NA not evaluable Hepatitis TRAE (grade 3-4)detailed results KEYNOTE-183, 2019 2.03 [0.07; 60.94]
2.03 [0.07 ; 60.94 ] KEYNOTE-183, 2019 1 0% 241 NA not evaluable Hyperthyroidism TRAE (grade 3-4)detailed results KEYNOTE-183, 2019 1.01 [0.02; 51.24]
1.01 [0.02 ; 51.24 ] KEYNOTE-183, 2019 1 0% 241 NA not evaluable Hypothyroidism TRAE (grade 3-4)detailed results KEYNOTE-183, 2019 1.01 [0.02; 51.24]
1.01 [0.02 ; 51.24 ] KEYNOTE-183, 2019 1 0% 241 NA not evaluable Infusion-related reactions TRAE (grade 3-4)detailed results KEYNOTE-183, 2019 1.01 [0.02; 51.24]
1.01 [0.02 ; 51.24 ] KEYNOTE-183, 2019 1 0% 241 NA not evaluable Myocarditis TRAE (grade 3-4)detailed results KEYNOTE-183, 2019 1.01 [0.02; 51.24]
1.01 [0.02 ; 51.24 ] KEYNOTE-183, 2019 1 0% 241 NA not evaluable Pneumonitis TRAE (grade 3-4)detailed results KEYNOTE-183, 2019 2.03 [0.07; 60.94]
2.03 [0.07 ; 60.94 ] KEYNOTE-183, 2019 1 0% 241 NA not evaluable Rash TRAE (grade 3-4)detailed results KEYNOTE-183, 2019 6.18 [0.31; 124.71]
6.18 [0.31 ; 124.71 ] KEYNOTE-183, 2019 1 0% 241 NA not evaluable Stevens-Johnson syndrome TRAE (grade 3-4)detailed results KEYNOTE-183, 2019 1.01 [0.02; 51.24]
1.01 [0.02 ; 51.24 ] KEYNOTE-183, 2019 1 0% 241 NA not evaluable Anaemia AE (grade 3-4)detailed results KEYNOTE-183, 2019 1.31 [0.64; 2.68]
1.31 [0.64 ; 2.68 ] KEYNOTE-183, 2019 1 0% 241 NA not evaluable Asthenia AE (grade 3-4)detailed results KEYNOTE-183, 2019 0.16 [0.01; 3.32]
0.16 [0.01 ; 3.32 ] KEYNOTE-183, 2019 1 0% 241 NA not evaluable Back pain AE (grade 3-4)detailed results KEYNOTE-183, 2019 0.10 [0.01; 1.80]
0.10 [0.01 ; 1.80 ] KEYNOTE-183, 2019 1 0% 241 NA not evaluable Constipation AE (grade 3-4)detailed results KEYNOTE-183, 2019 2.03 [0.07; 60.94]
2.03 [0.07 ; 60.94 ] KEYNOTE-183, 2019 1 0% 241 NA not evaluable Cough AE (grade 3-4)detailed results KEYNOTE-183, 2019 0.50 [0.02; 15.11]
0.50 [0.02 ; 15.11 ] KEYNOTE-183, 2019 1 0% 241 NA not evaluable Diarrhoea AE (grade 3-4)detailed results KEYNOTE-183, 2019 1.01 [0.14; 7.28]
1.01 [0.14 ; 7.28 ] KEYNOTE-183, 2019 1 0% 241 NA not evaluable Dizziness AE (grade 3-4)detailed results KEYNOTE-183, 2019 2.03 [0.07; 60.94]
2.03 [0.07 ; 60.94 ] KEYNOTE-183, 2019 1 0% 241 NA not evaluable Dyspnoea AE (grade 3-4)detailed results KEYNOTE-183, 2019 0.33 [0.03; 3.22]
0.33 [0.03 ; 3.22 ] KEYNOTE-183, 2019 1 0% 241 NA not evaluable Fatigue AE (grade 3-4)detailed results KEYNOTE-183, 2019 0.05 [0.00; 0.80]
0.05 [0.00 ; 0.80 ] KEYNOTE-183, 2019 1 0% 241 NA not evaluable Headache AE (grade 3-4)detailed results KEYNOTE-183, 2019 1.01 [0.02; 51.24]
1.01 [0.02 ; 51.24 ] KEYNOTE-183, 2019 1 0% 241 NA not evaluable Increased ALT AE (grade 3-4)detailed results KEYNOTE-183, 2019 3.13 [0.62; 15.84]
3.13 [0.62 ; 15.84 ] KEYNOTE-183, 2019 1 0% 241 NA not evaluable Nausea AE (grade 3-4)detailed results KEYNOTE-183, 2019 0.50 [0.02; 15.11]
0.50 [0.02 ; 15.11 ] KEYNOTE-183, 2019 1 0% 241 NA not evaluable Neutropenia AE (grade 3-4)detailed results KEYNOTE-183, 2019 1.90 [1.07; 3.37]
1.90 [1.07 ; 3.37 ] KEYNOTE-183, 2019 1 0% 241 NA not evaluable Peripheral oedema AE (grade 3-4)detailed results KEYNOTE-183, 2019 0.50 [0.02; 15.11]
0.50 [0.02 ; 15.11 ] KEYNOTE-183, 2019 1 0% 241 NA not evaluable Pneumonia AE (grade 3-4)detailed results KEYNOTE-183, 2019 1.09 [0.51; 2.31]
1.09 [0.51 ; 2.31 ] KEYNOTE-183, 2019 1 0% 241 NA not evaluable Pyrexia AE (grade 3-4)detailed results KEYNOTE-183, 2019 0.25 [0.03; 2.23]
0.25 [0.03 ; 2.23 ] KEYNOTE-183, 2019 1 0% 241 NA not evaluable Thrombocytopenia AE (grade 3-4)detailed results KEYNOTE-183, 2019 1.87 [0.75; 4.63]
1.87 [0.75 ; 4.63 ] KEYNOTE-183, 2019 1 0% 241 NA not evaluable 0.0 10.0 1.0 relative treatment effect www.metaEvidence.org 2024-10-06 19:53 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 115
- treatments: 847,982,359,575,577,576,869,1081,981,875,505,952,1021,1079,767,1071,1074,873,561